Dr. Emily Elizabeth Jonczak, MD

Dr. Jonczak practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Jonczak's NPI, 1417375973, was assigned on April 2, 2014. Dr. Jonczak graduated from St. George's University School of Medicine in 2014. Dr. Jonczak holds Florida license ME131757.

Dr. Jonczak's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Jonczak's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. Dr. Jonczak is also affiliated with Jackson Memorial Hospital. The medical group on file is University of Miami Health System.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Jonczak practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Jonczak's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Jonczak is board certified in internal medicine by the American Board of Internal Medicine. Dr. Jonczak is licensed in Florida.

Dmand AI lists chronic leukemia, colorectal cancer and prostate cancer among the conditions Dr. Jonczak treats.

CMS data shows 510 Medicare services from Dr. Jonczak across 6 procedure codes in 2024, for 112 Medicare patients. Medicare paid $33,001 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 112 Medicare patients who saw Dr. Jonczak in 2024. The largest group is 65 to 74, with 49 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 32% are also on Medicaid. Their average risk score is 2.64, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Jonczak's median patient age at 67, with 53% women.

In 2024, Dr. Jonczak wrote 529 Medicare Part D claims for 77 patients. 86% of them were for generic drugs. CMS names the drug for 353 of them, across 15 drugs with 11 or more claims each, at $985,703 in total drug cost. In 2023, CMS named 252 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Jonczak for performance year 2024, reported as part of a group. Dr. Jonczak accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Jonczak as offering telehealth.

Dmand AI links 16 papers to Dr. Jonczak, published from 2011 to 2025. 2025 was the busiest year, with 4. The most frequent topics are Bone Neoplasms and Magnetic Resonance Imaging. Dr. Jonczak has published most often in Cancers (Basel). Dr. Jonczak's most frequent co-authors are Jonathan C. Trent, MD, PhD, Ty Kanyn Subhawong, MD and Steven Bialick, DO, MS.

Dmand AI links Dr. Jonczak to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Gastrointestinal Stromal Tumors and Neoplasms, Connective Tissue.

CMS Open Payments shows 103 general payments to Dr. Jonczak from 22 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 39% of the total. SpringWorks Therapeutics, Inc. paid the most, $4,972.

Dr. Jonczak graduated from St. George's University School of Medicine in 2014.

Dr. Jonczak is in network with 10 carriers, including Elevance, Aetna and United Healthcare. PPO plans come from the most carriers, 6. Check the plan with the practice before a visit.